Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration

Cancer Gene Therapy

Volumn 7, Issue 1, 2000, Pages 83-90

  Hara, Isao ^a   Nagai, Hiroshi ^a   Miyake, Hideaki ^a   Yamanaka, Kazuki ^a   Hara, Shoji ^a   Micallef, Mark J ^b   Kurimoto, Masashi ^b   Gohji, Kazuo ^a   Arakawa, Soichi ^a   Ichihashi, Masamitsu ^a   Kamidono, Sadao ^a  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HAYASHIBARA BIOCHEMICAL LABORATORIES INC   (Japan)

Author keywords

Gene therapy; Interleukin 12; Interleukin 18; Renal cell carcinoma

Indexed keywords

CANCER VACCINE; INTERLEUKIN 12; MITOMYCIN C; RECOMBINANT INTERLEUKIN 18;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HELPER CELL; KIDNEY CARCINOMA; LYMPHOCYTE DEPLETION; MOUSE; MULTIMODALITY CANCER THERAPY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; TUMOR REJECTION;

ANIMALIA; MUS MUSCULUS;

EID: 0033953608     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700083     Document Type: Article

References (33)

1. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med. 1989;170:827-845.
2. Stern A, Podlaski FJ, Hulmes JD, et al. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci USA. 1990;87:6808-6812.
3. + NK cells. J Immunol. 1992;148:2429-2436.
4. Chan SH, Perussia B, Gupta JW, et al. Induction of interferon-γ production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med. 1991;173:869-879.
5. Gately MK, Desai BB, Wolitzky AG, et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol. 1991;147:874-882.
6. Gately MK, Warrier RR, Honasoge S, et al. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-γ in vivo. J Immunol. 1994;6:157-167.
7. Mu J, Zou JP, Yamamoto N, et al. Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res. 1995;55:4404-4408.
8. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 1993;178:1223-1230.
9. Cohen J. IL-12 deaths: explanation and a puzzle. Science. 1995;270:908.
10. Okamura H, Tsutusi T, Komatsu T, et al. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature. 1995;378:88-91.
11. Micallef MJ, Yoshida K, Kawai S, et al. In vivo antitumor effects of murine interferon-γ-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma ascites. Cancer Immunol Immunother. 1997;43:361-3671.
12. Micallef MJ, Ohtsuki T, Kohno K, et al. Interferon-γ-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-γ production. Eur J Immunol. 1996;26:1647-1651.
13. Kohno K, Kataoka J, Ohtsuki T, et al. IFN-γ-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts effect independently of IL-12. J Immunol. 1997;158:1541-1550.
14. Miller J, Germain RN. Efficient cell surface expression of class II MHC molecules in the absence of associated invariant chain. J Exp Med. 1986;164:1478-1489.
15. Southern PJ, Berg S. Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. Mol Cell Biol. 1982;3: 280-289.
16. Gately MK. Measurement of human and mouse interleukin-12. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, eds. Current Protocols in Immunology, Vol. 1. NY: John Wiley & Sons, Inc.; 1995:6.16.1-6.16.15.
17. Miyake H, Hara I, Yoshimura K, et al. Introduction of basic fibroblast growth factor gene into mouse renal cell carcinoma cell line enhances its metastatic potential. Cancer Res. 1996;56:2440-2445.
18. Colombo MP, Forni G. Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today. 1994;15:48-51.
19. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539-3543.
20. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood. 1994;84:4008-4027.
21. Caruso M, Pham NK, Kwong YL, et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci USA. 1996;93:11302-11306.
22. Cavallo F, Signorelli P, Giovarelli M, et al. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst. 1997;89:1049-1058.
23. Nishimura T, Watanabe K, Yahata T, et al. Application of interleukin 12 to antitumor cytokine and gene therapy. Cancer Chemother Pharmacol. 1996;38:S27-S34.
24. Rakhmilevich AL, Turner J, Ford MJ, et al. Gene gunmediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA. 1996;93:6291-6296.
25. Rodolfo M, Zilocchi C, Melani C, et al. Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens: comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines. J Immunol. 1996:157: 5536-5542.
26. Schmitt M, Ikeda H, Nagata Y, et al. Involvement of T-cell subsets and natural killer (NK) cells in the growth suppression of murine fibrosarcoma cells transfected with interleukin-12 (IL-12) genes. Int J Cancer. 1997;72:505-511.
27. Tahara H, Zeh HJI, Storkus WJ, et al. Fibroblasts genetically engineered to secrete interleukin 12 suppress tumor growth and induce antitumor immunity to murine melanoma in vivo. Cancer Res. 1994;54:182-189.
28. Tahara H, Zitvogel L, Storkus WJ, et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol. 1995;154:6466-6474.
29. Tan J, Newton CA, Djeu JY, et al. Injection of complementary DNA encoding interleukin-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model. Cancer Res. 1996;56:3399-3403.
30. Hara I, Hotta H, Sato N, Eto H, Arakawa S, Kamidono S. Rejection of mouse renal cell carcinoma elicited by local secretion of interleukin-2. Jpn J Cancer Res. 1996;87:724-729.
31. Martinotti A, Stoppacciaro A, Vagliani M, et al. CD4 T cells inhibit in vivo the CDS-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur J Immunol. 1995;25:137-146.
32. Ahn HJ, Maruo S, Tomura M, et al. A mechanism underlying synergy between IL-12 and IFN-γ-inducing factor in enhanced production of IFN-γ. J Immunol. 1997;159:2125-2131.
33. Dao K, Ohashi K, Kayano T, Kurimoto M, Okamura H. Interferon-γ-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cell. Cell Immunol. 1996;173:230-235.